<DOC>
	<DOCNO>NCT02872766</DOCNO>
	<brief_summary>43 Subjects ( 43 eye ) qualify participation undergo require screening procedure determine study eligibility . The surgical protocol involve apply riboflavin 0,22 % 0,25 % 20 minute . Then , eye expose UVA light KXL II system accord programmed treatment pattern . All use KXL II system accordance general instruction operator 's manual . All subject evaluate screening , Day 3 , 1 , 3 , 6 ,12 24 month treatment . Manual keratometry , manifest refraction , uncorrected visual acuity , best correct visual acuity , slit lamp biomicroscopy , pentacam measurement placido disc topography ( TMS ) , obtain baseline appropriate time treatment .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Corneal Cross Linking Treatment Myopia .</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<criteria>Provide write informed consent Willingness folow instruction comply schedule follow visit Having myopia manifest refraction spherical equivalent 1.00 2.50 D , cylindral component pl 0.75 D Social security insurance equivalent sensitivity use test article ( ) hypersensitivity local anesthesics Corneal pachymetry &lt; 480 micron Eyes keratoconus Eyes aphakic corneal intacs Previous ocular condition ( refractive error ) eye treat may predispose eye future complication . For example : History corneal disease ( e.g. , herpes simplex , recurrent erosion syndrome , corneal dystrophy , refractive keratotomy etc . ) , clinically significant corneal scar crosslinking treatment zone Pregnancy lactation Patients current condition , investigator 's opinion , would interfere prolong epithelial healing Taking Vitamin C ( ascorbic acid ) supplement within 1 week crosslinking treatment . Juridical protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>